Neuromuscular recovery (NMR) is a critical part of recovery from general anesthesia. Neostigmine is a choline esterase inhibitor and one of the leading agents which are used for NMR from non-depolarizing neuromuscular block. Its effect depends on competitive antagonism of the neuromuscular blocking agent (NMBA) in the neuromuscular junction (NMJ). Sugammadex is a new agent which has attracted attention with dramatically rapid NMR from non -depolarizing neuromuscular blocking agents (NDNMBAs). It effects via chemically antagonizing NMBAs. In this study, effects of neostigmine and sugammadex concerning recovery from general anesthesia for intracranial mass excision operations were compared. Totally 60 patients were included in the study. Neostigmine was used for 30 patients, and sugammadex was used for 30 patients. Evaluation criteria were the train of four (TOF), bispectral index (BIS), Glasgow Coma Scale (GCS), Modified Aldrete Score (MAS), Ramsey Sedation Score (RSS), vital signs and existed complications. It is observed that NMR and recovery from anesthesia were significantly shorter in the sugammadex group (p
___
1. Kalfas IH, Little JR. A postoperative survey of 4992 intracranial procedures. Neurosurgery 1988; 23: 343-347.
2. Paul AP, Vedantam A, Korula G, Chacko AG. A comparison of the recovery profiles of desflurane and isoflurane anesthesia in patients undergoing elective supratentorial craniotomy: A randomized controlled trial, Neurol India 2017; 65: 1053-1058.
3. Magorian TT, Lynam DP, Caldwell JE, Miller RD. Can early administration of neostigmine, in single or repeated doses, alter the course of neuromuscular recovery from a vecuroniuminduced neuromuscular blockade? Anesthesiology 1990; 73: 410-414.
4. Morgan G.E. and Mikhail M.S., Kolinesteraz inhibitörleri, in Klinik anesteziyoloji 2008, Güneş Tıp Kitabevleri: Ankara, Türkiye. p. 227-237.
5. Bom A, Bradley M, Cameron K, Clark JK, Van Egmond J, Feilden H, et al. A novel concept of reversing neuromuscular block: Chemical encapsulation of rocuronium bromide by a cyclodextrin-based synthetic host. Angewandte Chemie 2002; 41: 266-270.
6. Gijsenbergh F, Ramael S, Houwing N, Van Iersel T. First human exposure of Org 25969, a novel agent to reverse the action of rocuronium bromide. Anesthesiology 2005; 103: 695-703.
7. Sorgenfrei IF, Norrild K, Larsen PB, Stensballe J, Ostergaard D, Prins ME, et al. Reversal of rocuronium-induced neuromuscular block by the selective relaxant binding agent sugammadex: A dose-finding and safety study. Anesthesiology 2006; 104: 667-674.
8. De Boer HD, Van Egmond J, Van de Pol F, Bom A, Booij LHDJ. Sugammadex, a new reversal agent for neuromuscular block induced by rocuronium in the anesthetized Rhesus monkey. British Journal of Anesthesiology 2006; 96: 473-479.
9. Zhang M, Drug-specific cyclodextrins: The future of rapid neuromuscular block reversal. Drugs Future 2003; 28: 347-354.
10. Shields M, Giovannelli M, Mirakhur RK, Moppett I, Adams J, Hermens Y. Org 25969 (sugammadex), a selective relaxant binding agent for antagonism of prolonged rocuronium-induced neuromuscular block. British Journal of Anesthesiology 2006; 96: 36-43.
11. Della Rocca G, Pompei L, Pagan DE, Paganis C, Tesoro S, Mendola C, Boninsegni P, et al. Reversal of rocuronium-induced neuromuscular block with sugammadex or neostigmine: a large observational study. Acta Anaesthesiol Scand 2013; 57: 1138- 1145.
12. Ledowski T, Hillyard S, O'Dea B, Archer R, VilasBoas F, Kyle B. Introduction of sugammadex as standard reversal agent: Impact on the incidence of residual neuromuscular blockade and postoperative patient outcome. Indian J Anaesth 2013; 57: 46-51.
13. Woo T. and Kim K., Sugammadex versus neostigmine reversal of moderate rocuroniuminduced neuromuscular blockade in Korean patients Korean Journal of Anesthesiologists 2013; 65: 501-507.
14. Geldner G. and Niskanen M, A randomised controlled trial comparing sugammadex and neostigmine at different depths of neuromuscular blockade in patients undergoing laparoscopic surgery. Anaesthesia 2012; 67: 991-998.
15. Morgan G.E. and Mikhail M.S., Yoğun bakım, in Klinik Anesteziyoloji 2008, Güneş Tıp Kitabevleri: Ankara, Türkiye. p. 1018-1065
16. Soyalp C, Dostbil A, Çelik M, Ahıskalıoğlu A, Aksoy M, İnce İ, Karakaya MA. The effects of desflurane and remifentanyl anaesthesia compared to lumbar epidural analgesia combined with desflurane on recovery. Dicle Medical Journal 2014; 41: 640-646.
17. Hans D de Boer, 1,2 Jan van Egmond,2 Jacques J Driessen,2 and Leo HD Booij2 Update on the management of neuromuscular block: focus on sugammadex, Neuropsychiatr Dis Treat 2007; 3: 539-544.
18. Llaurado S, Sabate A, Ferreres E, Camprubi I, Cabrera A. Postoperative respiratory outcomes in laparoscopic bariatric surgery: Comparison of a prospective group of patients whose neuromuscular blockade was reverted with sugammadex and a historical one reverted with neostigmine. Rev Esp Anestesiol Reanim 2014; 61: 565-570.
19. Mohamed Naguib, Sugammadex: Another Milestone in Clinical Neuromuscular Pharmacology Medical Intelligence Vol. 104, No. 3, March 2007
20. Dahaba A.A. and Bornemann H, Effect of sugammadex or neostigmine neuromuscular block reversal on bispectral index monitoring of propofol/remifentanil anaesthesia. British Journal of Anaesthesia 2012; 108: 602.